F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

Oil Prices Drop Near Four-Month Low as Supply Glut and Chinese Economy Increases
Reportedly A.G. Lafley to Pass Reigns of P&G CEO to David Taylor
Baidu Profits in Second Quarter Offset by Higher Expenses
Economists Predict Solid Revenue Growth for Vermont
Swiss bank Vontobel Announces 24 Percent Increase in Profit in the First Half of
President Obama Visits Kenya, His Father’s Birth Place
National Highway Traffic Safety Administration Slaps $105M Fine on Fiat Chrysler
Wealthy, Well Educated People in Early 60’s More at Risk of Harmful Drinking
Amazon’s Strong Second Quarter Results Boost the Company’s Share
Weak PMI in China Raises Concern and Asian Shares Drop on Friday
Even with Lower Sales, Coca-Cola’s Profit Increases
Qualcomm Plans to Cut Jobs and May go in for a Spin Off